AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Harrison, New York.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone972-8684-3313
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees12
OptionableNot Optionable
AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions
What is AIT Therapeutics' stock symbol?
AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB."
How were AIT Therapeutics' earnings last quarter?
AIT Therapeutics Inc (OTCMKTS:AITB) posted its earnings results on Wednesday, February, 13th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.21) by $0.32. View AIT Therapeutics' Earnings History.
When is AIT Therapeutics' next earnings date?
Has AIT Therapeutics been receiving favorable news coverage?
Media stories about AITB stock have trended neutral this week, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AIT Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of AIT Therapeutics' key competitors?
Some companies that are related to AIT Therapeutics include T2 Biosystems (TTOO), RenovaCare (RCAR), Sensus Healthcare (SRTS), STRATA Skin Sciences (SSKN), iCAD (ICAD), RA Medical Systems (RMED), Apollo Endosurgery (APEN), Invo Bioscience (IVOB), CAS Medical Systems (CASM), Motus GI (MOTS), Arch Therapeutics (ARTH), Pro-Dex (PDEX), Alphatec (ATEC), Endologix (ELGX) and Repro-Med Systems (REPR).
Who are AIT Therapeutics' key executives?
AIT Therapeutics' management team includes the folowing people:
- Mr. Steven Adam Lisi, CEO & Chairman (Age 48)
- Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 45)
- Mr. Douglas J. Beck, Chief Financial Officer (Age 58)
- Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory Board
- Dr. Giora Davidai M.D., Chief Medical Officer
How do I buy shares of AIT Therapeutics?
Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AIT Therapeutics' stock price today?
One share of AITB stock can currently be purchased for approximately $5.09.
How big of a company is AIT Therapeutics?
AIT Therapeutics has a market capitalization of $43.77 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 12 workers across the globe.
What is AIT Therapeutics' official website?
How can I contact AIT Therapeutics?
AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313.
MarketBeat Community Rating for AIT Therapeutics (OTCMKTS AITB)
MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote "Outperform" if you believe AITB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days.
